Last reviewed · How we verify
NCT03395275
Intrathecal Morphine Microdose Method Sensory Changes
NA trial testing Quantitative Sensory Tests in Analgesic Drug Dependence. Withdrawn.
3 February 2023
Quick facts
| Lead sponsor | The University of Texas Medical Branch, Galveston |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Start date | 8 October 2018 |
| Primary completion | 3 February 2023 |
| Estimated completion | 3 February 2023 |
Drugs / interventions tested
- Quantitative Sensory Tests
- surveys
Conditions studied
- Analgesic Drug Dependence — all drugs for Analgesic Drug Dependence →
- Sensory Disorders — all drugs for Sensory Disorders →
- Chronic Pain — all drugs for Chronic Pain →
Sponsor
The University of Texas Medical Branch, Galveston
Who can join
Adults 18 to 75, any sex, with Analgesic Drug Dependence or Sensory Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Following the retrospective study on the effectiveness of the microdose method of intrathecal morphine therapy, the investigators are interested in measuring the sensory changes at 4 time points during the microdose method. The microdose method involves weaning the patient off oral opioids and maintaining an opioid-free period prior to initiating a very low opioid dose in intrathecal therapy. The microdose method is a standard of care. The study involves measuring sensory changes to hot, cold, and pressure. Data collection will be performed at regularly scheduled clinic visits, examining range of doses, pain scores,dose escalations, quantifiable psychosocial factors ( not captured in previous retrospective study), and changes in sensory thresholds.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03395275
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The University of Texas Medical Branch, Galveston trials
Trials by the same sponsor.
- NCT04095260 — Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes. · not yet recruiting
- NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment · Phase 2, PHASE3 · not yet recruiting
- NCT07337915 — Improving Sleep In Midlife Women · NA · recruiting
- NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
- NCT07087743 — Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03395275 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Texas Medical Branch, Galveston
- Last refreshed: 7 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03395275.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing